Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Eight-week, Randomized, Double-blind, Parallel Group, Multicenter, Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskiren Administered Alone and in Combination With Ramipril in Patients With Hypertension and Diabetes Mellitus

NCT00219089 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00219089
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00219089 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Eight-week, Randomized, Double-blind, Parallel Group, Multicenter, Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskiren Administered Alone and in Combination With Ramipril in Patients With Hypertension and Diabetes Mellitus
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2004
Completion date
August 31, 2005
Enrollment
839 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension, diabetes mellitus